Testosterone Therapy in Castration Resistant Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Square Wave Testosterone Therapy in Castration Resistant Prostate Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03734653
• Other study ID #: 18-0821.cc
• Status: Active, not recruiting
• Phase: Early Phase 1
• Start date: January 18, 2019
• Est. completion date: August 2025

Study information

• Verified date: March 2024
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-labeled, single-arm, interventional pilot study. It is being done to determine the feasibility of the administration of transdermal testosterone alternating with enzalutamide, as well as the safety and efficacy.

Description:

The primary endpoint of this trial is to determine the feasibility of the administration of transdermal testosterone alternating with enzalutamide. High dose testosterone has shown activity in phase II studies of patients with castration resistant metastatic prostate cancer; however, these studies have generally employed the intramuscular formulation. It has been hypothesized that the transdermal formulation will show activity but will have less potential for toxicity due to extremely high levels of circulating testosterone (i.e. thrombotic events). In addition, this will allow for a steady state of elevated testosterone, rather than the peaks and troughs seen with the IM approach.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: August 2025
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Provision to sign and date the consent form

2. Male and age > or = 18 years old

3. Stated willingness to comply with all study procedures and be available for the duration of the study

4. Histologically or cytologically proven adenocarcinoma of the prostate

5. Ongoing ADT for prostate cancer with a GnRH analogue/antagonist or bilateral orchiectomy for at least 6 months prior to day 1

6. Patients on a first generation anti-androgen (e.g. bicalutamide, flutamide, nilutamide) must have at least a 6-week washout prior to randomization and must show continued PSA progression

7. Serum testosterone level <50ng/dL at the screening visit

8. Progressive disease at screening as defined by one or more of the following criteria:

• PSA progression: minimum of 2 rising values within an interval of >1 week between values. And a value at screening of >1ng/mL

• Soft tissue progression on CT or MRI based on RECIST 1.1 criteria or progression of bone disease according to PCWG3 criteria

9. Patients worst pain in the last 24 hours must rank less than 4 on a 0-10 scale and patients cannot be on daily narcotic medications to treat cancer-related pain. This assessment must occur within the screening window and be documented in the patient's medical record.

10. Acceptable Clinical laboratory values at Screening Visit which include:

• Absolute neutrophil count = 1000/uL; platelet count = 100,000/uL, hemoglobin = 8g/dL

• Total bilirubin = 1.5xULN (unless documented Gilbert's); alanine aminotransferase or aspartate aminotransferase = 2.5xULN

• Creatinine = 2mg/dL

• Hemoglobin = 17.5 g/dL

11. Evidence of metastatic disease at any time point on axial imaging or bone scan, or previous biopsy. Stage IV pelvic lymph node involvement is acceptable

12. Must use a condom if having sex with a pregnant woman

13. A male patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration

14. Patients may have received any number of lines of therapy for castration resistant disease

Exclusion Criteria:

1. Requires urinary catheterization for voiding due to obstruction secondary to prostatic enlargement that is well documented to be due to prostate cancer or benign prostatic hyperplasia

2. Evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone due to a potential tumor flare (e.g. high-risk bone lesions which may result in fracture or spinal cord compression

3. Clinically significant cardiovascular disease as evidenced by any of the following:

• Myocardial infarction with 6 months of screening

• uncontrolled angina within 3 months of screening

• NYHA class 3 or 4 congestive heart failure

• clinically significant ventricular arrhythmia

• Mobitz II/Second degree/or 3rd degree heart block without a pacemaker in place; uncontrolled HTN (systolic >180mmHg or diastolic >105mmHg at screening

4. Previous exposure to a second-generation anti-androgen i.e enzalutamide or apalutamide

5. Received investigational agent within 2 weeks of screening

6. Therapy with antineoplastic systemic chemotherapy or biological therapy within 2 weeks of screening

7. Radiation therapy within 2 weeks of screening

8. History of a prior malignancy (excluding an adequately treated basal or squamous cell skin cancer, superficial bladder cancer, or a cancer in situ) within 5 years prior to study enrollment

9. History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agent

10. Known or suspected brain metastasis or active leptomeningeal disease

11. History of seizure at any time in the past. Also, history of loss of consciousness or transient ischemic attack within 12 months of Day 1 visit

12. Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements

Related Conditions & MeSH terms

• Castration-Resistant Prostate Cancer
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Transdermal Testosterone
Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
• Standard of Care, Enzalutamide
Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.

Locations

Country	Name	City	State
United States	University of Colorado Hospital	Aurora	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	Cancer League of Colorado

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of the Administration of Transdermal Testosterone Alternating with Enzalutamide	This study will be considered feasible if at least 50% of patients approached for participation enroll and if at least 50% of patients that initiate therapy do not withdraw consent for participation.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Safety of the Administration of Transdermal Testosterone Alternating with Enzalutamide	Safety will be assessed based on the Common Terminology Criteria of Adverse Events (CTCAE) v5.0 criteria, in which rates of Grade 1-5 AE will be assessed, with a prticular attention to grade 3-5 events	Study start date to study end date, up to 12 months, or until patient death
Secondary	Prostate Specific Antigen (PSA) Response Rate	PSA response rates as measured by serum PSA at designated study visits. Response will be defined as a decline in the serum PSA of 50% from baseline value at start of study.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Time to Radiographic Progression	Time to radiographic progression as measured by Response Evaluation Criteria in Solid Tumors (RECIST).	Study start date to study end date, up to 12 months, or until patient death
Secondary	Time to Radiographic Progression	Time to radiographic progression as measured by Prostate Cancer Clinical Trials Working Group 3 (PCWG3) imaging criteria.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Time to PSA Progression	This will be defined by the PCWG3.	Study start date to study end date, every four weeks, up to 12 months, or until patient death
Secondary	Maximum Decrease in PSA	PSA will be assessed at baseline and every four weeks. Maximum decrease assessed through these measurements.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Physical Function Change	Assessed through handgrip exercises.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Physical Function Change	Assessed through chair rise exercises.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Patient Activation	Assessed using the Self-Efficacy for Physical Activity Scale (SEPA), which uses a 5 point Likert scale.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Reported Fatigue	Measured by the Functional Assessment of Cancer Therapy-Fatigue (FACT-Fatigue 13).	Study start date to study end date, up to 12 months, or until patient death
Secondary	Patient Mood and Depression Evaluation	Measured through the Center for Epidemiologic Studies-Depression Scale (CES-D), which uses a point system based on responses ranging from "not at all" to "all the time."	Study start date to study end date, up to 12 months, or until patient death
Secondary	Bone Health	Standard bone densometry assessment will be used to calculate T and Z score to determine normal, osteopenic, or osteoporotic bone mineral density.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Body Composition	Measured by a DXA scanner. Free fat mass and lean body mass will be assessed to determine sarcopenic obesity.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Quality of Life Assessment	Measured by the Functional Assessment of Cancer Therapy-Prostate (FACT-P).	Study start date to study end date, up to 12 months, or until patient death
Secondary	Change in Hormones	Change in testosterone, estrogen, and sex hormone binding globulin.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Self-Reported Physical Function	Measured by the PROMIS-PA.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Energy Expenditure	Measured by hood assessment.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Change in Max Repetition	Measured by subject's maximal leg press over time in the energy-balance laboratory.	Study start date to study end date, up to 12 months, or until patient death
Secondary	Change in Spontaneous Physical Activity and Sedentary Time	Measured through accelerometry. Patients will wear an accelerometer for one week at initiation and again one month later.	Study start date to study end date, up to 12 months, or until patient death
Secondary	PSA Response in this Cohort of Patients vs Historical Cohorts	Assessed through IM testosterone historical data.	Study start date to study end date, up to 12 months, or until patient death